Recombinant Human Bone Morphogenetic Protein-2 Binding and Incorporation in PLGA Microsphere Delivery Systems

REFERENCES

• Lee H. J. M. D. Taylor, G. L. AmidonBiopharmaceutical properties and pharmacokinetics of peptide and protein drugs. Peptide-base drug design controlling transport and metabolism, . American Chemical Society, Washington, D.C. 1995; 69–91
   Google Scholar
• Kenley R. A., Yim K., Abrams J., Ron E., Turek T., Marden L. J., Hollinger J. O. Biotechnology and bone graft substitutes. Pharm. Res. 1993; 10(10)1393–1401
   PubMed Web of Science ®Google Scholar
• Ron E., Schaub R. G., Turek T. J. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins. US Patent 5171579, 1992
   Google Scholar
• Sigurdsson T. J., Lee M. B., Kubota K., Turek T. J., Wozney J. M., Wikesjo U. M. Periodontal repair in dogs: recombinant human bone morphogenetic protein-2 significantly enhances periodontal regeneration. J. Periodontol. 1995; 66(2)131–138
   PubMed Web of Science ®Google Scholar
• Sigurdsson T. J., Fu E., Wikesjo U. M. E. Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. Clinical Oral Implants Research 1997; 8(5)367–374
   PubMedGoogle Scholar
• Lucas P. A., Syftestad G. T., Goldberg V. M., Caplan A. I. Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a collagenous delivery vehicle. J. Biomed. Mater. Res. 1989; 23((A1 Suppl))23–39
   PubMedGoogle Scholar
• Lynch S. E., Buser D., Hernandez R. A., Weber H. P., Stich H., Fox C. H., Williams R. C. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs. J. Periodontol. 1991; 62(11)710–716
   PubMed Web of Science ®Google Scholar
• Kenley R., Marden L., Turek T., Jin L., Ron E., Hollinger J. O. Osseous regeneration in the rat calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). J. Biomed. Mater. Res. 1994; 28(10)1139–1147
   PubMed Web of Science ®Google Scholar
• Sandhu H. S., Kanim L. E., Kabo J. M., Toth J. M., Zeegan E. N., Liu D., Seeger L. L., Dawson E. G. Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Spine 1995; 20(24)2669–2682
   PubMed Web of Science ®Google Scholar
• Sandhu H. S., Kanim L. E., Kabo J. M., Toth J. M., Zeegen E. N., Liu D., Delamarter R. B., Dawson E. G. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996; 21(18)2115–2122
   PubMedGoogle Scholar
• Sandhu H. S., Kanim L. E., Toth J. M., Kabo J. M., Liu D., Delamarter R. B., Dawson E. G. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 without decortication of osseous elements [published erratum appears in Spine, 1997 Oct 15;22(20):2463]. Spine 1997; 22(11)1171–1180
   PubMedGoogle Scholar
• Sandhu H. S., Boden S. D. Biologic enhancement of spinal fusion. Orthop. Clin. North Am. 1998; 29(4)621–631
   PubMedGoogle Scholar
• Duggirala S. S., Mehta R. C., DeLuca P. P. Interaction of recombinant human bone morphogenetic protein-2 with poly(d,l lactide-co-glycolide) microspheres. Pharm. Dev. Technol. 1996; 1(1)11–19
   PubMedGoogle Scholar
• Kinoshita A., Shigeru O., Takahasi K., Yokota S., Ishikawa I. Periodontal regeneration by application of recombinant human bone morphogenetic protein-2 to horizontal circumferential defects created by experimental periodontitis in beagle dogs. J. Periodontol. 1997; 68: 103–109
   PubMed Web of Science ®Google Scholar
• Kirker-Head C. A., Gerhart T. N., Schelling S. H., Hennig G. E., Wang E., Holtrop M. E. Long-term healing of bone using recombinant human bone morphogenetic protein 2. Clin. Orthop. 1995; 318: 222–230
   Google Scholar
• Nevins M., Kirker-Head C., Wozney J. A., Palmer R., Graham D. Bone formation in the goat maxillary sinus induced by absorbable collagen sponge implants impregnated with recombinant human bone morphogenetic protein-2. Int. J. Periodontics Restorative Dent. 1996; 16(1)8–19
   PubMedGoogle Scholar
• Alonso M. J., Cohen S., Park T. G., Gupta R. K., Siber G. R., Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res. 1993; 10(7)945–953
   PubMed Web of Science ®Google Scholar
• Johnson O. L., Cleland J. L., Lee H. J., Charnis M., Duenas E., Jaworowicz W., Shepard D., Shahzamani A., Jones A. J., Putney S. D. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 1996; 2(7)795–799
   PubMed Web of Science ®Google Scholar
• Okada H., Doken Y., Ogawa Y., Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm. Res. 1994; 11(8)1143–1147
   PubMed Web of Science ®Google Scholar
• Howell T. H., Fiorellini J., Jones A., Alder M., Nummikoski P., Lazaro M., Lilly L., Cochran D. A feasibility study evaluating rhBMP-2/absorbable collagen sponge device for local alveolar ridge preservation or augmentation. Int. J. Periodontics Restorative Dent. 1997; 17(2)124–139
   PubMed Web of Science ®Google Scholar
• Boyne P. J., Marx R. E., Nevins M., Triplett G., Lazaro M., Lilly L., Alder M., Nummikoski P. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int. J. Periodontics Restorative Dent. 1997; 17: 10–25
   Google Scholar
• Urist M. R., O'Connor B. T., Burwell R. G. Bone Grafts, Derivatives, and Substitutes. Butterworth-Heinemann, Oxford 1994
   Google Scholar
• Pavanetto F., Conti B., Genta Y., Giunchedi P. Solvent evaporation, solvent extraction and spray drying for polylactide microsphere preparation. Int. J. Pharm. 1992; 84: 151–159
   Web of Science ®Google Scholar
• Guo F. Preparation methods of biodegradable microspheres on bovine serum albumin loading efficiency and release profiles. Drug Dev. Ind. Pharm. 1994; 20: 2535–2545
   Web of Science ®Google Scholar
• Uchida T., Yoshida K., Goto S. Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. J. Microencapsul. 1996; 13(2)219–228
   PubMed Web of Science ®Google Scholar
• Jeyanthi R., Mehta R. C., Thanoo B. C., DeLuca P. P. Effect of processing parameters on the properties of peptide-containing PLGA microspheres. J. Microencapsul. 1997; 14(2)163–174
   PubMed Web of Science ®Google Scholar
• Duggirala S. S., Rodgers J. B., DeLuca P. P. The evaluation of lyophilized polymer matrices for administering recombinant human bone morphogenetic protein-2 [published erratum appears in Pharm. Dev. Technol., 1996 Oct;1(3):317]. Pharm. Dev. Technol. 1996; 1(2)165–174
   PubMedGoogle Scholar
• Snell F. D., Ettre L. S. In-vitro Degradation and Swelling of PLGA Microspheres. Encyclopedia of Industrial Chemical Analysis, Interscience Publishers, New York 1974; vol. 18
   Google Scholar
• Redmon M. P., Hickey A. J., DeLuca P. P. Prednisolone-21-acetate polyglycolic acid microspheres: influence of matrix characteristics on release. J. Controlled Release 1989; 9: 99–109
   Web of Science ®Google Scholar
• Mehta R. C., Jeyanthi R., Calis S., Thanoo B. C., Burton K. W., DeLuca P. P. Biodegradable microspheres as depot system for parenteral delivery of peptide drugs. J. Controlled Release 1994; 29: 375–384
   Web of Science ®Google Scholar
• Sato T., Kanke M., Schroeder H. G., DeLuca P. P. Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques. Pharm. Res. 1988; 5(1)21–30
   PubMed Web of Science ®Google Scholar